$AUROPHARMA Gains After Securing USFDA Approval for Generic Tofacitinib Tablets

$AUROPHARMA 's shares moved higher after the company announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and commercialize Tofacitinib Tablets (5 mg and 10 mg) in the United States. Key Highlights of the Approval Regulatory Clearance: The company has obtained final USFDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths. Generic Equivalent: The product is the generic version of Pfizer's blockbuster drug, Xeljanz. Therapeutic Applications: Tofacitinib is indicated for the treatment of eligible adult patients suffering from Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis. Manufacturing & Launch: The product will be manufactured at APL Healthcare Unit IV, a subsidiary of Aurobindo Pharma, and is set for immediate commercialization in the U.S. market. Market Opportunity and Business Impact Addressable Market: According to industry estimates, the U.S. market for Tofacitinib Tablets is valued at approximately $494 million. Positive Investor Sentiment: Following the announcement, Aurobindo Pharma's stock witnessed strong buying interest, advancing toward the ₹1,467 mark on the exchanges. Strengthening Product Portfolio: With this latest approval, $AUROPHARMA Pharma's cumulative USFDA ANDA approvals have risen to 586, comprising 561 final approvals and 25 tentative approvals, further reinforcing its presence in the U.S. generics market. The approval is expected to enhance $AUROPHARMA 's product portfolio and support its growth strategy in the highly competitive U.S. pharmaceutical market. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.